Eidelman Virant Capital cut its stake in Eli Lilly and Company (NYSE:LLY – Get Rating) by 54.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,675 shares of the company’s stock after selling 2,000 shares during the period. Eidelman Virant Capital’s holdings in Eli Lilly and were worth $479,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Tudor Investment Corp Et Al increased its stake in shares of Eli Lilly and by 11.3% during the third quarter. Tudor Investment Corp Et Al now owns 9,882 shares of the company’s stock valued at $2,283,000 after purchasing an additional 1,002 shares in the last quarter. FinTrust Capital Advisors LLC increased its stake in shares of Eli Lilly and by 4.2% during the third quarter. FinTrust Capital Advisors LLC now owns 1,679 shares of the company’s stock valued at $388,000 after purchasing an additional 67 shares in the last quarter. Atria Investments LLC increased its stake in shares of Eli Lilly and by 2.7% during the third quarter. Atria Investments LLC now owns 34,726 shares of the company’s stock valued at $8,023,000 after purchasing an additional 898 shares in the last quarter. EP Wealth Advisors LLC increased its stake in shares of Eli Lilly and by 2,931.2% during the third quarter. EP Wealth Advisors LLC now owns 229,822 shares of the company’s stock valued at $1,412,000 after purchasing an additional 222,240 shares in the last quarter. Finally, Laffer Tengler Investments bought a new position in shares of Eli Lilly and during the third quarter valued at approximately $35,000. Institutional investors and hedge funds own 82.75% of the company’s stock.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction on Friday, May 27th. The shares were sold at an average price of $318.98, for a total value of $63,796,000.00. Following the sale, the insider now directly owns 104,833,810 shares in the company, valued at approximately $33,439,888,713.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total transaction of $313,440.00. Following the completion of the sale, the chief accounting officer now owns 6,274 shares in the company, valued at $1,966,522.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 848,630 shares of company stock worth $259,239,945. 0.12% of the stock is owned by corporate insiders.
Eli Lilly and (NYSE:LLY – Get Rating) last released its earnings results on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.30. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The company had revenue of $7.81 billion for the quarter, compared to analysts’ expectations of $7.29 billion. During the same quarter in the previous year, the company earned $1.87 EPS. Eli Lilly and’s revenue for the quarter was up 14.8% on a year-over-year basis. On average, research analysts forecast that Eli Lilly and Company will post 8.27 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, June 10th. Investors of record on Monday, May 16th were paid a dividend of $0.98 per share. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.30%. The ex-dividend date was Friday, May 13th. Eli Lilly and’s dividend payout ratio (DPR) is 58.07%.
A number of equities analysts have weighed in on the stock. Wells Fargo & Company raised their target price on shares of Eli Lilly and from $280.00 to $305.00 in a research note on Friday, April 29th. Morgan Stanley lifted their target price on shares of Eli Lilly and from $364.00 to $369.00 in a research report on Friday, April 29th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. The Goldman Sachs Group lifted their target price on shares of Eli Lilly and from $234.00 to $264.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Finally, StockNews.com downgraded shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 13th. Three research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and currently has an average rating of “Moderate Buy” and a consensus target price of $311.00.
Eli Lilly and Company Profile (Get Rating)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
- The Rebound In Winnabego Is On
- Global Events Could Be A Boon For Potash Stocks
- SeaWorld Entertainment Stock Can be Caught on the Downdraft
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.